{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:57:19Z","timestamp":1776236239970,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MedComm"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    This phase II trial evaluated the efficacy and safety of combining niraparib with the PD\u20101 inhibitor HX008 in patients with metastatic breast cancer who had germline DNA damage response (DDR) mutations. The study included 37 patients, divided into a primary cohort of HER2\u2010negative individuals with germline BRCA1\/2 or PALB2 mutations (\n                    <jats:italic>n<\/jats:italic>\n                    = 29) and an exploratory cohort of patients who were either HER2\u2010negative with other DDR mutations, had brain metastases, or were HER2\u2010positive (\n                    <jats:italic>n<\/jats:italic>\n                    = 8). The main cohort achieved an objective response rate (ORR) of 76% and a disease control rate (DCR) of 97%, with a median progression\u2010free survival (PFS) of 7.3\u00a0months. The exploratory cohort had an ORR of 25% and a DCR of 75%, while patients with brain metastases showed a 40% ORR. Among treatment\u2010related adverse events of Grade 3 or higher, the most frequently observed were anemia (35.1%), thrombocytopenia (10.8%), and neutropenia (8.1%). No treatment\u2010related deaths were reported. Somatic XPO1 mutations correlated with better response. Somatic TP53 mutations significantly correlated with shorter PFS, while ASXL1 mutations correlated with longer PFS. This chemotherapy\u2010free regimen demonstrates promising efficacy and a tolerable safety profile in patients with metastatic breast cancer and germline DDR mutations, providing a novel therapeutic option for this patient population, even those with brain metastases.\n                  <\/jats:p>","DOI":"10.1002\/mco2.70684","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T08:10:15Z","timestamp":1773562215000},"source":"Crossref","is-referenced-by-count":0,"title":["Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD\u20101 Inhibitor and Niraparib in GErm\u2010Line\u2010mutAted Metastatic Breast Cancer"],"prefix":"10.1002","volume":"7","author":[{"given":"Jian","family":"Zhang","sequence":"first","affiliation":[{"name":"Phase I Unit Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqun","family":"Du","sequence":"additional","affiliation":[{"name":"Phase I Unit Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchun","family":"Meng","sequence":"additional","affiliation":[{"name":"Phase I Unit Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizi","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"},{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"},{"name":"Department of Medical Oncology Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuchen","family":"Shao","sequence":"additional","affiliation":[{"name":"Phase I Unit Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Liu","sequence":"additional","affiliation":[{"name":"Phase I Unit Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Mu","sequence":"additional","affiliation":[{"name":"Phase I Unit Fudan University Shanghai Cancer Center  Shanghai China"},{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology Shanghai Medical College Fudan University  Shanghai China"},{"name":"Department of Breast Surgery Fudan University Shanghai Cancer Center  Shanghai China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0140"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00400-2"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0310"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1029"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211020528"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.837963"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1218"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11048-5"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0063"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1020"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-2652"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30324-7"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102324"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abp9530"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.01.001"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802905"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.549220"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw199"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3215"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.05.009"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz012"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2098"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdz005"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.01.008"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e15019"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2020.11713"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e21090"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.6266"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2554"}],"container-title":["MedComm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mco2.70684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mco2.70684","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mco2.70684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:57:50Z","timestamp":1776232670000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mco2.70684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/mco2.70684"],"URL":"https:\/\/doi.org\/10.1002\/mco2.70684","archive":["Portico"],"relation":{},"ISSN":["2688-2663","2688-2663"],"issn-type":[{"value":"2688-2663","type":"print"},{"value":"2688-2663","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"article-number":"e70684"}}